ATE275394T1 - R- und s- enantiomere getrennteteile enthaltende dosierungsformen - Google Patents

R- und s- enantiomere getrennteteile enthaltende dosierungsformen

Info

Publication number
ATE275394T1
ATE275394T1 AT98910863T AT98910863T ATE275394T1 AT E275394 T1 ATE275394 T1 AT E275394T1 AT 98910863 T AT98910863 T AT 98910863T AT 98910863 T AT98910863 T AT 98910863T AT E275394 T1 ATE275394 T1 AT E275394T1
Authority
AT
Austria
Prior art keywords
enantiomeric
dosage forms
dosage form
separate parts
enantiomers
Prior art date
Application number
AT98910863T
Other languages
German (de)
English (en)
Inventor
Julian Clive Gilbert
Andrew J M Richards
Hazel Judith Bardsley
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704978.7A external-priority patent/GB9704978D0/en
Priority claimed from GBGB9719261.1A external-priority patent/GB9719261D0/en
Application filed by Arakis Ltd filed Critical Arakis Ltd
Application granted granted Critical
Publication of ATE275394T1 publication Critical patent/ATE275394T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT98910863T 1997-03-11 1998-03-11 R- und s- enantiomere getrennteteile enthaltende dosierungsformen ATE275394T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9704978.7A GB9704978D0 (en) 1997-03-11 1997-03-11 Dosage forms
GBGB9719261.1A GB9719261D0 (en) 1997-09-10 1997-09-10 Dosage forms
US09/038,873 US6056968A (en) 1997-03-11 1998-03-11 Pharmaceutical drug dosage forms providing different release rates
PCT/GB1998/000726 WO1998040053A1 (en) 1997-03-11 1998-03-11 Dosage forms comprising separate portions of r- and s-enantiomers

Publications (1)

Publication Number Publication Date
ATE275394T1 true ATE275394T1 (de) 2004-09-15

Family

ID=27268767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98910863T ATE275394T1 (de) 1997-03-11 1998-03-11 R- und s- enantiomere getrennteteile enthaltende dosierungsformen

Country Status (15)

Country Link
US (2) US6056968A (enExample)
EP (1) EP0969818B1 (enExample)
JP (1) JP2001514651A (enExample)
CN (1) CN1251987A (enExample)
AT (1) ATE275394T1 (enExample)
AU (1) AU741821B2 (enExample)
BR (1) BR9808325A (enExample)
CA (1) CA2285407C (enExample)
DE (1) DE69826113T2 (enExample)
ES (1) ES2227814T3 (enExample)
HU (1) HUP0000759A3 (enExample)
IL (1) IL131713A (enExample)
NO (1) NO994412L (enExample)
PL (1) PL335619A1 (enExample)
WO (1) WO1998040053A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
HUP0104420A2 (en) * 1998-12-02 2002-08-28 Darwin Discovery Ltd Therapeutic composition containing a new form of tramadol and its use
WO2000043003A1 (en) * 1999-01-21 2000-07-27 Darwin Discovery Limited The therapeutic use of r-warfarin as anticoagulant
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
PE20010623A1 (es) * 1999-10-05 2001-07-07 Gruenenthal Chemie Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
EP1313460A2 (en) * 1999-11-09 2003-05-28 Darwin Discovery Limited Therapeutic use and formulation of (-)-tramadol
DE10004926A1 (de) 2000-02-04 2001-08-09 Gruenenthal Gmbh Verfahren zur enzymatischen Racematspaltung von Aminomethyl-Aryl-Cyclohexanol-Derivaten
AU3582101A (en) 2000-03-01 2001-09-12 Euro-Celtique S.A. The treatment of functional gastrointestinal disorders
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
BR0114395A (pt) * 2000-10-03 2005-08-16 Penwest Pharmaceuticals Compan Composição farmacêutica para administração por suprimento via oral
EP1335707A4 (en) * 2000-10-24 2005-07-06 Smithkline Beecham Corp NEW CARVEDILOL FORMULATIONS
US6562871B1 (en) * 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
IN191028B (enExample) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
EP1562552A1 (en) * 2002-11-08 2005-08-17 Egalet A/S Controlled release carvedilol compositions
WO2004056336A2 (en) * 2002-12-20 2004-07-08 Ranbaxy Laboratories Limited Controlled release, multiple unit drug delivery systems
WO2004071501A1 (en) * 2003-02-10 2004-08-26 Shire Biochem Inc. Enantiomeric amphetamine compositions for the treatment of adhd
WO2004103361A2 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited A pharmaceutical dosage form of citalopram
WO2004110411A2 (fr) * 2003-06-06 2004-12-23 Ethypharm Comprime orodispersible multicouche
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
US8734850B2 (en) 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
JP4965261B2 (ja) * 2004-10-01 2012-07-04 日本臓器製薬株式会社 固形医薬製剤
CN101242856A (zh) 2005-09-09 2008-08-13 莱博法姆公司 持续药物释放的组合物
WO2007080509A2 (en) * 2006-01-12 2007-07-19 Wockhardt Ltd Sustained release compositions of alfuzosin
ES2744495T3 (es) * 2006-03-30 2020-02-25 Nippon Zoki Pharmaceutical Co Preparación farmacéutica sólida
PL2120570T3 (pl) * 2007-02-12 2012-10-31 Vyrix Pharmaceuticals Inc Leczenie współwystępującego przedwczesnego wytrysku i zaburzenia wzwodu prącia
DK2114147T3 (da) 2007-02-12 2012-06-25 Dmi Biosciences Inc Reduktion af bivirkninger af tramadol
EP2322168A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818541A (en) * 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
US5145866A (en) * 1991-04-22 1992-09-08 Hoechst-Roussel Pharmaceuticals Incorporated Method of treating anxiety with the aid of r(+)-3-amino-1-hydroxy-pyrrolidin-2-one
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
GB9412689D0 (en) * 1994-06-23 1994-08-10 Chiroscience Ltd Cytotoxic agent and its use

Also Published As

Publication number Publication date
HUP0000759A2 (hu) 2000-10-28
ES2227814T3 (es) 2005-04-01
IL131713A (en) 2004-08-31
DE69826113D1 (de) 2004-10-14
IL131713A0 (en) 2001-03-19
CN1251987A (zh) 2000-05-03
JP2001514651A (ja) 2001-09-11
HUP0000759A3 (en) 2000-11-28
EP0969818A1 (en) 2000-01-12
BR9808325A (pt) 2000-05-16
CA2285407A1 (en) 1998-09-17
CA2285407C (en) 2006-08-01
US6056968A (en) 2000-05-02
NO994412D0 (no) 1999-09-10
DE69826113T2 (de) 2005-01-20
US6221394B1 (en) 2001-04-24
WO1998040053A1 (en) 1998-09-17
AU6508998A (en) 1998-09-29
NO994412L (no) 1999-10-20
PL335619A1 (en) 2000-05-08
AU741821B2 (en) 2001-12-13
EP0969818B1 (en) 2004-09-08

Similar Documents

Publication Publication Date Title
ATE275394T1 (de) R- und s- enantiomere getrennteteile enthaltende dosierungsformen
EP1458708A4 (en) HETEROARYLSUBSTITUTED TRIAZOLE MODULATORS OF THE METABOTROPIC GLUTAMATAR RECEPTOR 5
DK1414816T3 (da) Stabil polymorf af flibanserin, teknisk fremgangsmåde til fremstilling deraf og anvendelse deraf til lægemiddelfremstilling
NO20041740L (no) Tidsstyrt vedvarende frigivelses multipartikulaere doseringsformer av propranolol
PT1155692E (pt) Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido
AU2002360949A1 (en) 17Alpha-ALKYL-17Beta-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17Alpha-ALKYL-17Beta-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS
NO20035496D0 (no) Substituerte sulfonamidforbindelser, fremgangsmåte for deres anvendelse sommedikament til behandling av CNS-forstyrrelser, overvekt og typeII-diabetes
DK1162982T3 (da) Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
IL139227A0 (en) N-substituted aminotetralins as ligands for the neuropeptide yy5 receptor useful in the treatment of obesity and other disorders
IS7497A (is) (1a,3a,5a)(3-amínómetýl bísýkló[3.2.0]hept-3-ýl)l-ediksýra, lyfjasamsetningar og notkun efnasambands til framleiðslu á lyfjum
MA25567A1 (fr) Nouvelle composition et son utilisation
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
DK1144386T3 (da) Polymorf form af telmisartan, fremgangsmåde til fremstilling deraf og anvendelse deraf til fremstilling af et lægemiddel
CA2285037A1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
NO20054739L (no) Metode for okning av oral biotilgjengelighet av S-2'-("1-(2-etylbutyl)cyklo-heksyl!carbonyl!amino)fenyl!-2-metylpropanetioat
AU2003293593A8 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
ITTO990784A0 (it) Procedimento di rafforzamento di attivita' antitumorale di farmacigrezzi, composizione contenente un farmaco grezzo rafforzante l'atti-
WO2000059489A8 (en) Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
PT1194415E (pt) Novos derivados da piperazinil-alquil-tiopirimidina composicoes farmaceuticas que os contem e um processo de preparacao da substancia activa
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
EE200100596A (et) Ülipuhas (1R,2S,4R)-(-)-2-[(2'-{N,N-dimetüülamino}etoksü)]-2-[fenüül]-1,7,7-tri[metüül]bitsüklo[2.2.1 ]heptaan ja selle farmatseutiliselt vastuvõetavad happeliitsoolad ning nimetatud ühendite, samutiravimite, mis sisaldavad üks või enam nimetatud üh
MY130814A (en) Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
DK1071397T3 (da) Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel
AU3749195A (en) Bis-2-aminopyridines, preparation method therefor and use tereof for controlling parasitic infections
NO20022896L (no) Substituerte 1- og 2-naftol mannich baser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties